Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
11
|
| pubmed:dateCreated |
1980-8-28
|
| pubmed:abstractText |
Neocarzinostatin (NCZ), a new antitumor antibiotic, was administered to 19 patients with bladder cancer, 16 patients with prostatic cancer, and 3 patients with hepatoma. All patients had objectively measurable metastatic lesions including 21 with palpable nodes or subcutaneous nodules, 10 with pulmonary nodules as demonstrated by chest x-ray, 4 with malignant hepatomegaly, and 3 with bidimensional pelvic masses as demonstrated by CT scanning. Sixty-five courses of NCZ were administered via an intravenous bolus daily for five days with dosages ranging from 1500 to 3000 U/m2. Immediate toxicity was not dose-limiting except for 1 episode of anaphylaxis and 1 of acute renal failure. Myelotoxicity was delayed, dose-dependent, noncumulative, and dose-limiting. Thrombocytopenia was prolonged or irreversible in 5 cases. The maximally tolerated dose was 2750 U/m2. One patient with NCZ-associated pulmonary fibrosis and 1 with biopsy-proven hepatitis are discussed in detail. Neocarzinostatin demonstrated minimal therapeutic activity (1 partial remission) in patients with bladder cancer. There was no response in patients with prostatic cancer or hepatoma.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
0008-543X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
1
|
| pubmed:volume |
45
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
2836-42
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:6445776-Adult,
pubmed-meshheading:6445776-Aged,
pubmed-meshheading:6445776-Antibiotics, Antineoplastic,
pubmed-meshheading:6445776-Carcinoma, Transitional Cell,
pubmed-meshheading:6445776-Drug Administration Schedule,
pubmed-meshheading:6445776-Drug Evaluation,
pubmed-meshheading:6445776-Female,
pubmed-meshheading:6445776-Hematoma,
pubmed-meshheading:6445776-Humans,
pubmed-meshheading:6445776-Leukopenia,
pubmed-meshheading:6445776-Liver,
pubmed-meshheading:6445776-Male,
pubmed-meshheading:6445776-Middle Aged,
pubmed-meshheading:6445776-Neoplasm Metastasis,
pubmed-meshheading:6445776-Prostatic Neoplasms,
pubmed-meshheading:6445776-Respiratory Function Tests,
pubmed-meshheading:6445776-Thrombocytopenia,
pubmed-meshheading:6445776-Urinary Bladder Neoplasms,
pubmed-meshheading:6445776-Zinostatin
|
| pubmed:year |
1980
|
| pubmed:articleTitle |
Phase II trial of neocarzinostatin in patients with bladder and prostatic cancer: toxicity of a five-day iv bolus schedule.
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Case Reports
|